E-PUB AHEAD OF SCHEDULE: Bentham Science
Publishers are pleased to offer electronic publication of
accepted papers prior to scheduled publication. These peer-reviewed
papers can be cited using the date of access and the unique
DOI number. Any final changes in manuscripts will be made
at the time of print publication and will be reflected in
the final electronic version of the issue. Articles ahead
of schedule may be ordered by pay-per-view at the relevant
links by each article stated via the E-Pub
Ahead of Schedule.
Disclaimer: Articles appearing in E-Pub Ahead-of-Schedule
sections have been peer-reviewed and accepted for publication
in this journal and posted online before scheduled publication.
Articles appearing here may contain statements, opinions,
and information that have errors in facts, figures, or interpretation.
Accordingly, Bentham Science Publishers, the editors
and authors and their respective employees are not responsible
or liable for the use of any such inaccurate or misleading
data, opinion or information contained of articles in the
E-Pub Ahead-of-Schedule.
State of Art and Recent Developments of Anti-Cancer Strategies Based on TRAIL
Bernardi S, Secchiero P and Zauli G
[Abstract] [FULL-TEXT INQUIRY] [PMID:
22114983 PubMed - indexed for MEDLINE] [BSP/PRA/E-Pub/00055]
Anticancer Drug Discovery from the Marine Environment
Nastrucci C, Cesario A and Russo P
[Abstract] [FULL-TEXT INQUIRY] [PMID:
22216781 PubMed - indexed for MEDLINE] [BSP/PRA/E-Pub/00057]
Emerging Role of Cetuximab in the Treatment of Colorectal Cancer
Papa A, Rossi L, Lo Russo G, Giordani E, Spinelli GP, Zullo A, Petrozza V and Tomao S
[Abstract] [FULL-TEXT INQUIRY] [PMID:
22264223 PubMed - indexed for MEDLINE] [BSP/PRA/E-Pub/00058]
Abstracts
State of Art and Recent Developments of Anti-Cancer Strategies Based on TRAIL
Bernardi S, Secchiero P and Zauli G
[FULL-TEXT INQUIRY] [PMID: 22114983 PubMed - indexed for MEDLINE] [BSP/PRA/E-Pub/00055]
Multicellular organisms require apoptosis whereby the human body eliminates unnecessary and/or damaged cells. Apoptosis, or programmed cell death, can indeed be considered as a constitutive anti-cancer mechanism that seems to be defective in more than 50% of cancers. Molecular insights on the biology of the apoptotic process have led to the development of new anti-cancer strategies aiming at recovering and stimulating this process. Preclinical and clinical studies of our and other groups have demonstrated that targeting the extrinsic apoptotic pathway by various death receptors agonists is a safe and effective anti-cancer strategy, which thus may become a new cornerstone of cancer therapy. Here we review the most recent acquisitions and patents on TRAIL or TRAIL mimetics, as well as the combination therapies that could be used with them.
[Back to top]
Anticancer Drug Discovery from the Marine Environment
Nastrucci C, Cesario A and Russo P
[Abstract] [FULL-TEXT INQUIRY] [PMID:
22216781 PubMed - indexed for MEDLINE] [BSP/PRA/E-Pub/00057]
Discovery, isolation, biochemical/pharmacological characterization, pre-clinical and clinical trials of drugs derived from the marine environment are continuously developing and increasing. One of the most promising area is cancer therapy. Currently, there are two drugs approved by the Food and Drug Administration (FDA) and European Agency for the Evaluation of Medicinal Products (EMA) in cancer treatment, namely Cytarabine (Cytosar-U1®) and Eribulin (E7389 or Halaven®). Trabectedin (ET-743 or Yondelis1®), approved by EMA, is completing key Phase III studies in the U.S. for final approval. It was estimated that 118 marine natural products (MNPs) are currently in preclinical trials, 22 MNPs in clinical trials and 3 MNPs on the market. The characteristics and selectivity profiles of new drugs for cancer therapy, as well as drugs disclosed in related patent applications, will be the focus of this review, providing a brief and ready to use reference.
[Back to top]
Emerging Role of Cetuximab in the Treatment of Colorectal Cancer
Papa A, Rossi L, Lo Russo G, Giordani E, Spinelli GP, Zullo A, Petrozza V and Tomao S
[Abstract] [FULL-TEXT INQUIRY] [PMID:
22264223 PubMed - indexed for MEDLINE] [BSP/PRA/E-Pub/00058]
CRC is the fourth most frequently diagnosed tumor and the second leading cause of cancer death in the United States. KRAS mutations occur in 35–45% of metastatic-CRC and preclude responsiveness to cetuximab or panitumumab. However, less than 20% of KRAS wild-type (wt) patients achieve objective response. Alterations of BRAF/NRAS/PIK3CA/PTEN, have independently been found to give rise to resistance. The first-line trials with cetuximab chemotherapy are conflicting, because of the many differences among prospective and retrospective evaluations. In neoadjuvant regimens, cetuximab with CT obtained a significant and early increase of the RR. In second-line studies cetuximab improved RR and PFS. Cetuximab has not reported any benefit neither in adjuvant nor in trials with bevacizumab. In third-line studies cetuximab-irinotecan is associated with a significant advantage in ORR, mTTP and OS. Value of KRAS is questioned, since a high percentage of KRAS-wt patients has no benefit with cetuximab. More and more data on the molecular patterns of these tumors underline their biological complexity. Cetuximab treatment is usually well tolerated. Moreover, toxicity seems to correlate with response to treatment. This patent review focuses on recent advances in the treatment of CRC with cetuximab including several novel therapeutic protocols of intervention.
[Back to top]
|
